Effect of physical therapy on breast cancer related lymphedema:protocol for a multicenter, randomized, single-blind, equivalence trial by Tambour, Mette et al.
Tambour et al. BMC Cancer 2014, 14:239
http://www.biomedcentral.com/1471-2407/14/239STUDY PROTOCOL Open AccessEffect of physical therapy on breast cancer
related lymphedema: protocol for a multicenter,
randomized, single-blind, equivalence trial
Mette Tambour1, Berit Tange1, Robin Christensen2,3 and Bibi Gram4,5*Abstract
Background: Physical therapy treatment of patients with lymphedema includes treatment based on the principles
of ‘Complete Decongestive Therapy’ (CDT). CDT consists of the following components; skin care, manual lymphatic
drainage, bandaging and exercises. The scientific evidence regarding what type of treatment is most effective is
sparse. The objective of this study is to investigate whether CDT is equally effective if it includes manual lymphatic
drainage or not in the treatment of arm lymphedema among patients with breast cancer.
Methods/Design: A randomized, single-blind, equivalence trial. A total of 160 breast cancer patients with arm
lymphedema will be recruited from 3 hospitals and randomized into one of two treatment groups A: Complete
Decongestive Therapy including manual drainage or B: Complete Decongestive Therapy without manual lymphatic
drainage. The intervention period will be approximately 4 weeks followed by a 6 month follow-up period (7 months
from baseline). Primary outcome variable: the percentage volume reduction of lymphedema (%) from baseline to
7 months. Secondary outcome variables: Differences from baseline to week 4 and from week 4 to month 7 in
circumference of the arm (cm), body weight (kg), patient sensation of heaviness (scale range: 0–10), patient
sensation of tension (scale range: 0–10), and quality of life (EQ-5D-5 L-questionnaire).
All measurements are standardized and will be performed before randomization, after 4 weeks and after 7 months.
Discussion: This randomized controlled study seeks to provide data on an effective treatment for patients with
breast cancer related arm lymphedema and which at the same time causes minimal patient inconvenience.
Trial registration: ClinicalTrials.gov: Identifier NCT02015897
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Breast cancer is the most common type of cancer in
women and in 2011, 4607 women in Denmark were di-
agnosed with breast cancer [1]. One of the well-known
complications of breast cancer treatment is secondary
lymphedema; an accumulation of protein-rich interstitial
fluid due to the insufficient capacity of the lymphatic
system. Axillary lymph-node dissection and subsequent
radiation therapy are the most common causes of arm
lymphedema [2,3]. The incidence of lymphedema as a* Correspondence: bgram@health.sdu.dk
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unless otherwise stated.sequelae to breast cancer treatment ranges from 6-50%,
depending on the surgical procedure in the axilla and
the type of the radiation therapy [2,4]. The reported
prevalence relies among other things on the definition of
lymphedema and which techniques are used to measure
it [5]. Lymphedema occurs most often within the first
year following the treatment [6,7] and 77% of the pa-
tients develop lymphedema within the first three years
post-surgery [8].
Lymphedema is a chronic condition and when un-
treated, the risk of worsening of the lymphedema over
time in terms of volume and stage of tissue fibrosis in-
creases [9-11]. In addition to the cosmetic deformities,
lymphedema causes impaired physical mobility, mentalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[12,13] and higher incidence of erysipelas [12,14].
Physical therapy treatment of patients with lymphedema
is based on the principles of ‘Complete Decongestive
Therapy’ (CDT). CDT consists of the following compo-
nents; skin care, manual lymphatic drainage, bandaging
and exercises. Traditionally, the bandages used in CDT
have been short-stretch bandages. In Denmark, the most
commonly used manual lymphatic drainage method is
described by Földi [15-17]. The treatment is based on
manual lymphatic drainage 4–5 times weekly and each
treatment takes 30–45 minutes. However, standardization
between different treatment locations and among treating
physiotherapists does not exist.
The scientific evidence regarding what type of treatment
or combination of treatments is most effective is sparse.
Studies [2,3,7,14] have focused on time-consuming man-
ual lymphatic drainage, but the scientific evidence is not
consistent [18-20]. The lack of robust evidence may be a
contributory cause to the variation of available treatment
options among different treatment locations and among
treating physiotherapists.
This includes both the combination of treatment
methods used and the time spent on each treatment. Fur-
thermore, the type of bandages used varies. Traditionally,
the patients receive the manual lymphatic drainage in
combination with the replacement of the bandage i.e. 4–5
times weekly, but a new type of bandage may only require
replacement two or three times weekly [21]. Reduced re-
placement of the bandage leads to fewer manual lymph-
atic drainage treatments and it is unknown whether use of
the relatively new but fairly common bandage, Coban™2
Lite, alone can constitute the treatment.
In a recent systematic review [18], the authors con-
cluded that there was not sufficient scientific evidence
supporting the use of manual lymphatic drainage in pre-
venting or treating lymphedema. Furthermore, the au-
thors found that the methodological quality of the studies
reviewed was poor and with clinical and statistical in-
consistencies between the various studies. Therefore,
there is a need for well-designed, high quality studies
with follow-up.
The hypothesis of this study is that skin care and
guidance of physical activity combined with Coban™2
Lite bandage alone is equally effective as Complete
Decongestive Therapy including skincare and guidance of
physical activity, manual lymphatic drainage and Coban™2
Lite bandage.
Objectives
Complete Decongestive Therapy is equally effective whether
it includes manual lymphatic drainage or not in the
treatment of arm lymphedema among patients with
breast cancer.Methods/Design
Trial design
The study is a randomized, single blinded, equivalence
trial aiming to determine whether an applied compos-
ite treatment is equally good if one of its components,
manual lymphatic drainage, is removed. The design is il-
lustrated in Figure 1.
The intervention period is approximately 4 weeks
followed by 6 months follow-up period. Overall length
of the study is 7 months. Primary endpoint will be 7 months
from baseline.
The patients complete baseline measurements before
the randomization.
Participants
Patients with breast cancer related lymphedema will be
recruited from the Hospital of Southwest Jutland, Lille-
baelt Hospital, and the Hospital of Southern Jutland.
The following eligibility criteria will be used to deter-
mine if a patient can be included:
Inclusion criteria
 Breast cancer diagnosis regardless of the date of
operation and identified lymphedema
 Ultrasound scanning of the axilla in order to exclude
local relapse
 Lymphedema > 2 cm and stage II-III [22]
 Completed radiotherapy and/or chemotherapy at
least 2 months prior to inclusion
Exclusion criteria
 Relapse of breast cancer
 Untreated infection
 Untreated heart failure
 Untreated renal failure
 Untreated deep venous thrombosis in the arm
 Inability to participate in physical therapy
treatments and/or inability to understand the
instructions
Intervention
Treatment groups
The treatment of the patients will be conducted at the
departments of physical therapy, Hospital of Southwest
Jutland (Esbjerg), Lillebaelt Hospital (Vejle), and the
Hospital of Southern Jutland (Aabenraa). The treatment
will be performed by lymphedema physiotherapists.
The number of patients included in the study is ex-
pected to be equally distributed between the 3 centers.
The patients will be randomized into two treatment
groups at each treatment site. The intervention period
for both groups will be minimum 2 weeks. In approx.
three weeks, the lymphedema is expected to be treated
Enrolment Baseline Intervention Follow-up
(Week -1 to Week 0)        (Week 0) (Week 0 to Week 4) Week 4             Month 7
Intervention B
Information
Enrolment
Written informed 
consent
Visit 1
Randomization
Intervention A Visit 2 Visit 3
Figure 1 Flow-chart: equivalence trial – lymphedema study.
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surements. The circumference of the arm will be mea-
sured at seven different locations on the arm at each
treatment (twice a week). When two consecutive mea-
surements are stationary (< 0.5 cm difference in three
out of five measurements), the active treatment period
will end and a permanent and individually tailored com-
pression sleeve/garment will be ordered. The treatment
will continue until the sleeve is made and can be given
to the patient.Treatment group A The treatment group A will receive
CDT-treatment as offered today at the Hospital of
Southwest Jutland, Esbjerg. The treatment includes:
 Skin care
 Manual lymphatic drainage
 Bandaging using Coban™2 Lite
 Guidance on physical activity
The patients will receive the manual lymphatic drain-
age for 30 minutes twice a week. Total treatment time
for each CDT-treatment session will be one hour.Table 1 Outcomes and variables assessed during the trial
period
Variable Baseline
visit 1
4 weeks
visit 2
7 months
visit 3
Age X
Body height,cm X
Arm lymphedema volume, ml X X XTreatment group B Treatment for group B includes:
 Skin care
 Bandaging using Coban™2Lite
 Guidance on physical activity
Treatment time for each session will be 30 minutes
and will be given twice a week.
All measurements and questionnaires will be performed
before randomization, after approximately 4 weeks and
after 7 months (Table 1). The measurements will be per-
formed by non-treating personnel.Circumference of the arm, cm X X X
Body weight, kg X X X
Sensation of heaviness, score X X X
Sensation of tension, score X X X
Quality of life (EQ-5D-5L), score X X XSpecification of each treatment component
Skin care In order to maintain the integrity of the skin,
at each treatment the arm is bathed and treated with
softening and unscented lotion.Manual lymphatic drainage Manual lymphatic drain-
age aims to remove excess interstitial fluid and increase
lymphatic transport. The treatment method used is ac-
cording to descriptions by Földi [15-17]. The manual
lymphatic drainage is a gentle massage and the move-
ments are slow and rhythmical. The method consists of
4 basic techniques with a pressure phase and a relax-
ation phase.
Bandaging Coban™2 Lite is a two-component compres-
sion system with a comfort layer close to the skin and a
self-adherent external compression layer. The comfort
layer is applied with minimal overlap and without ten-
sion whereas the compression layer is applied with 50%
overlap and at full stretch, corresponding to a pressure
of approximately 30 mmHg. The bandage is retained
until the next treatment.
Guidance on physical activity In order to maintain/
increase the mobility, the patients are encouraged to main-
tain normal function and information about the muscle
pump is provided.
Guidance of sleeve treatment in the observation period
The sleeve is considered to be a permanent assistive device
and when given to the patients, they will be instructed in ap-
plying the sleeve. Additionally, it will be recommended that
they keep the sleeve on every day from morning till night.
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Primary outcome measure: The percentage volume reduc-
tion of arm lymphedema (%) from baseline to 7 months.
Secondary outcome measure: Differences in circumfer-
ence of the arm (cm), bodyweight (kg), patient sensation
of heaviness (scale range: 0–10), patient sensation of
tension (scale range: 0–10), and quality of life (EQ-5D-
5 L-questionnaire).
Percentage volume reduction of arm lymphedema (%)
from baseline to week 4.
Percentage volume reduction of arm lymphedema (%)
from week 4 to week 7.
Length of treatment period until stable circumference
of the arm (days).
All measurements are standardized and will be per-
formed before randomization, after approximately 4 weeks
and after 7 months (Table 1).Measurements
Arm volume (ml): Inverse Water Displacement Volumetry
method [23] using Bravometer (Novuqare BV, PJ Horst,
NL).
Circumference (cm) of the arm using measuring tape:
Starting from the wrist, 5 circumference measures will be
noted: wrist (1 measure) forearm (2 measures) and upper
arm (2 measures) [24].
Patient sensation of heaviness: Scale ranging from 0–10
(0: no heaviness, 10: worst imaginable heaviness).
Patient sensation of tension: Scale ranging from 0–10
(0: no tension, 10: worst imaginable tension).
Quality of life: EQ-5D-5 L questionnaire (www.euro-
qol.org) [25].Sample size
The margin of equivalence, Δ, was defined as less than
12% points and the range −12% to +12% points thus
is predefined as an acceptable range of imprecision
(i.e., 95% confidence interval). This margin is based
on clinically and statistically important differences as
well as ethical criteria, cost and feasibility. In a two
one-sided tests (TOST) analysis for additive equivalence
of two-sample normal means with bounds −12 and 12
for the mean difference and a significance level of 0.05,
assuming a null difference and a common standard devi-
ation of 25%, a sample size of 76 patients with arm lymph-
edema per group is required to obtain a power of at
least 0.8. It was decided to enroll 160 patients in the
intention-to-treat (ITT) population. Secondarily to ex-
plore a potential difference between the groups, including
160 patients with a two-sided significance level of 0.05,
assuming a common SD of 25%, a sample size of 80 per
group has a power of 85.5% to detect a mean difference of
12% points.Randomization and allocation concealment
After the baseline assessment, the participants will be
randomly assigned to either treatment A or treatment B.
The randomization sequence will be created using SAS
(SAS 9.2) statistical software stratifying patients by
center with a 1:1 allocation using random block sizes
of 2, 4 and 6. The allocation sequence will be concealed
from the researcher enrolling and assessing partici-
pants in sequentially numbered, opaque, sealed and
stapled envelopes. Aluminum foil inside the envelope
will be used to render the envelope impermeable to
intense light.
The patients will be randomized (1:1) in one of the 2
groups:
1. Treatment-group A: standard treatment offered at
the hospital containing skincare, manual lymphatic
drainage, bandaging and guidance on physical
activity.
2. Treatment-group B: standard treatment except for
the manual lymphatic drainage. The treatment will
include skin-care, bandaging and guidance on
physical activity.
Statistical analyses
All data analyses will be carried out according to a pre-
established analysis plan and all analyses will be done
using SAS software (v. 9.2; SAS Institute Inc., Cary, NC,
USA). All descriptive statistics and tests will be reported
in accordance with the CONSORT statement for non-
inferiority/equivalence trials [26], which is the recommen-
dation of the “Enhancing the QUAlity and Transparency
Of health Research” (EQUATOR) network [27]. In order
to evaluate the empirical distributions of the continuous
outcomes, visual inspection of the studentized residuals
will be applied to evaluate whether the assumption of nor-
mality is reasonable.
Baseline demographic and clinical characteristics will
be reported descriptively for all patients in the full ana-
lysis set.
The primary analyses will be based on the ‘full analysis
set’, referred to as the intention-to-treat (ITT) popula-
tion. Missing data following baseline measurements will
be replaced using a non-responder imputation (i.e., base-
line observation carried forward) [28]. For assessments of
change from baseline, analyses of covariance (ANCOVA)
will be applied, with treatment assignment serving as the
main factor and the baseline value as covariate. Point esti-
mates and 95% confidence intervals (95% CIs) will be pro-
vided for the difference in adjusted mean change from
baseline between the two treatment groups.
For the discrete (dichotomous) data, the estimate of
the proportion of responders (with 95% CIs) within
each treatment group, as well as the 95% CIs for the
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will be presented.
Equivalence approach to analysis set: In order to demon-
strate equivalence the entire 2-sided 95% CI lies within −12%
points and +12% points. Thus, the per-protocol population,
which includes the subset of patients from the ITT popula-
tion who had no relevant protocol deviations, will be used
to confirm the primary efficacy (equivalence) end point.
Ethics
Prior to inclusion in the study, all participants will re-
ceive written and oral information about the study and
informed consent will be obtained from all participants
before enrollment in the study. The participants are
allowed to withdraw from the project without any fur-
ther explanations or consequences. Patients who do not
wish to participate in the study will receive the standard
hospital treatment of lymphedema.
The hospital’s doctors refer patients with lymphedema
to physical therapy. At the first meeting with the physio-
therapist, patients who are assessed to be in need of
Complete Decongestive Therapy will be informed about
the study. Written materials will be handed out at the first
meeting and it will be emphasized to the patient that at
the next appointment, if needed, there will be the oppor-
tunity to be accompanied by an observer. A written in-
formed consent will be obtained at the latest on the third
appointment or within a week from the first contact.
The study is registered with The Danish Data Protection
Agency, and in ClinicalTrials.gov (NCT02015897) www.
clinicaltrials.gov, and approved by The Regional Scientific
Ethical Committee for Southern Denmark (S-20130091).
Participation in the study is not considered to be hazard-
ous to the patient and no side effects associated with treat-
ment are expected.
Discussion
In clinical practice it is important to investigate the
methods used and elucidate those which are most effect-
ive. Several studies [18] have been published focusing on
the effect of Complete Decongestive Therapy (CDT), an
often used method in the treatment among breast cancer
patients with arm lymphedema. Manual lymphatic drain-
age is a time-consuming component in CDT. However,
there is not sufficient scientific evidence supporting the
use of manual lymphatic drainage in preventing or treat-
ing arm lymphedema. Moreover, there is focus on the
issue of resources; how we can identify the most effective
arm lymphedema treatment and achieve the desired clin-
ical benefit with minimal patient inconvenience.
This study aims to investigate if prioritizing the well-
known components in the CDT-treatment differently
can provide equally good effect. All treatment methods
used in the study are a part of everyday clinical practice.The participants will be recruited from and treated at
three hospitals in Denmark located in the region of
Southern Denmark. This setting will enable a bigger
sample size and with 7 months follow-up it will be pos-
sible to include long term monitoring. Additionally, the
study may, in the long term, lead to a standardized
method in the treatment of arm lymphedema.
This study will contribute to setting more focus on
scientific decision making in clinical practice. The know-
ledge from this study can be implemented into the
treatment of the patients since the study is based on an
approach used in the clinical setting.
The results will be disseminated to all groups with a
vested interest including (1) the scientific and professional
community; (2) the research participants, and (3) the gen-
eral public.
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